Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

ADC deals focus on linker technology

by Ann M. Thayer
April 11, 2016 | A version of this story appeared in Volume 94, Issue 15

Regeneron Pharmaceuticals has licensed technology from AstraZeneca’s MedImmune arm for making antibody-drug conjugates (ADCs) as cancer treatments. In exchange for a fee and milestone payments, Regeneron gets rights to use MedImmune’s method for linking a pyrrolobenzodiazepine-based cytotoxic drug to an antibody. Similarly, Oxford BioTherapeutics has licensed Nerviano Medical Sciences’ drug-linker technology. Nerviano will make and supply the cytotoxic-drug-and-linker combination, which is based on DNA-intercalating duocarmycin analogs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.